Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.

A number of other equities research analysts have also commented on EKSO. Lake Street Capital decreased their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a report on Tuesday, January 14th.

Ekso Bionics Trading Down 2.9 %

Shares of EKSO stock opened at $0.53 on Friday. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $11.72 million, a P/E ratio of -0.82 and a beta of 1.46. Ekso Bionics has a 12-month low of $0.47 and a 12-month high of $2.16. The firm has a 50-day moving average price of $0.62 and a 200 day moving average price of $0.84.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.